Home / Resources and Insights / Expansion Plan Announced during 2024 DCAT Week
Expansion Plan Announced during 2024 DCAT Week
Less than 1 min read time
WuXi STA is proceeding with a major multi-site, global expansion plan to enhance its manufacturing capabilities and capacities.
WuXi STA is proceeding with a major multi-site, global expansion plan to enhance its manufacturing capabilities and capacities. Yu Lu, the Chief Business Officer of WuXi STA and Head of WuXi TIDES, detailed the expansion efforts across several key sites at the DCAT Member Company Announcement Forum held on March 18th, 2024, at DCAT Week.
The expansion efforts across several key sites, including the unveiling of its 169-acre active pharmaceutical ingredient (API) manufacturing facility in Taixing, China, alongside existing drug-product manufacturing facilities in Wuxi City, China, and Couvet, Switzerland, and forthcoming sites in Middletown, Delaware, and Tuas, Singapore.
Related Reading
WuXi STA Forms Strategic Partnership with Beta Pharma
STA will Accelerate Process R&D and Manufacturing of Late Phase and Commercial Targets STA Pharmaceutical Co., Ltd., (WuXi STA) –...
New Blow-Fill-Seal Aseptic Filling Line
New Capability Spotlight: We just launched a new Blow-Fill-Seal (BFS) aseptic filling line at our drug product site in Wuxi...
WuXi STA launched a new PSD-4 spray dryer at our Taixing API manufacturing facility in China
WuXi STA continues to expand spray-dried dispersion (SDD) capabilities with the launch of a new PSD-4 spray dryer at our Taixing API...